Project Grant R21AI203182
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $263K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Forest Hills, TN 37215, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University Medical Center $262,388 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how the RNA binding protein HNRNPA2B1 regulates macrophage responses to Mycobacterium tuberculosis infection. The research examines alternative splicing as a mechanism controlling the balance between MTB virulence and host antimicrobial defenses. The award funds work to define how...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $418,816 on September 19, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize early T cell responses in tuberculosis infection using a non-human primate model. The project investigates the role of unconventional T cell subsets (CD1-restricted, MR1-restricted, and gamma-delta T cells) in containing acute Mycobacterium tuberculosis infection. The research uses...
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $315,700 on January 29, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research elucidating spatio-temporal innate immune cell modulation of Mycobacterium tuberculosis stress response and replication heterogeneity. The project investigates how spatial organization of tuberculosis lesions in the lung...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts General Hospital $798,107 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish a tissue-based understanding of tuberculosis-associated lung fibrosis and post-TB lung disease pathology. The project creates a baseline understanding of molecules and cells driving fibrogenesis during TB infection, with the goal of identifying adjunctive therapies to modulate tissue...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services National Institutes of Health, awarded Beth Israel Deaconess Medical Center, Inc. $1,296,750 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel trivalent adjuvanted tuberculosis vaccine. The research will characterize and advance a trivalent TB vaccine candidate consisting of three antigens—PPE20 (RV1387), ESXG (RV0287), and...
- The National Institute of Allergy and Infectious Diseases awarded Baylor College of Medicine $752,172 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a mechanistic study of an RNA translocase via integrative multi-resolution approach. The research investigates how mycobacteria persist in the host by examining a conserved bifunctional RNA helicase and nuclease enzyme found across mycobacterium species. The enzyme is thought to promote...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $281,500 on August 3, 2026, to investigate human neutralizing autoantibodies to interferon-gamma underlying mycobacterial diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research addresses the hypothesis that tuberculosis in some patients is caused by interferon-gamma autoantibodies with lower titer and/or lower affinity than those...
- The National Institute of Allergy and Infectious Diseases awarded Seattle Children's Research Institute $1,033,950 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a tuberculosis vaccine regimen optimized to induce lung-resident T cells. The project, titled "A Prime-Pull TB Vaccine Regimen Optimized to Induce Lung-Resident T Cells," focuses on identifying and testing mRNA-lipid nanoparticle vaccine candidates designed to generate...
- The National Institute of Allergy and Infectious Diseases awarded the Trustees of Boston University $245,250 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study the phenotypes and genesis of arginase 1-positive myeloid cells in pulmonary tuberculosis using a genetic mouse model of chronic TB. The research uses the B6.SST1S mouse model, which develops human-like organized necrotic granulomas after aerosol, intravenous, or subcutaneous infection...
- The National Institute of Allergy and Infectious Diseases awarded the University of California Irvine $205,216 on July 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to discover and characterize proteins required for Mycobacterium tuberculosis heme degradation. The research aims to identify additional proteins in the MTB heme catabolism pathway beyond the known MHUD protein, which catalyzes iron release from heme. The project will investigate the fate of MHUD...